Predictors and risks for death in a population-based study of persons with IBD in Manitoba

Gut

Volumn 64, Issue 9, 2015, Pages 1403-1411

  Bernstein, Charles N ^a   Nugent, Zoann ^a,b,c   Targownik, Laura E ^a   Singh, Harminder ^a,b,c   Lix, Lisa M ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b University of Manitoba IBD Clinical and Research Centre ^*  (Canada)

^c CANCERCARE MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANADA; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; DISEASE CLASSIFICATION; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SURGERY; HUMAN; INCIDENCE; LUNG CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; PNEUMONIA; POPULATION RESEARCH; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RESPIRATORY TRACT DISEASE; SEPSIS; SEX DIFFERENCE; SOCIAL STATUS; SUICIDE; ULCERATIVE COLITIS; CASE CONTROL STUDY; CAUSE OF DEATH; COLITIS, ULCERATIVE; CONFIDENCE INTERVAL; EPIDEMIOLOGY; FACTUAL DATABASE; INFLAMMATORY BOWEL DISEASES; KAPLAN MEIER METHOD; PREDICTIVE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX RATIO; SURVIVAL; UNIVERSITY HOSPITAL;

AGE DISTRIBUTION; CASE-CONTROL STUDIES; CAUSE OF DEATH; COLITIS, ULCERATIVE; CONFIDENCE INTERVALS; CROHN DISEASE; DATABASES, FACTUAL; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INFLAMMATORY BOWEL DISEASES; KAPLAN-MEIER ESTIMATE; MALE; MANITOBA; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS;

EID: 84941284736     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307983     Document Type: Article

References (41)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.
2. Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Aliment Pharmacol Ther 2007;25:861-70.
3. Duricova D, Pedersen N, Elkjaer M, et al. Overall and cause-specific mortality in Crohn's disease: a meta-analysis of population-based studies. Inflamm Bowel Dis 2010;16:347-53.
4. Bewtra M, Kaiser LM, Ten Have T, et al. Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis 2013;19:599-613.
5. Jess T, Gamborg M, Munkholm P, et al. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol 2007;102:609-17.
6. Jess T, Loftus EV Jr, Velayos FS, et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gut 2006;12:669-76.
7. Hutfless SM, Weng X, Liu L, et al. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007;133:1779-86.
8. Bernstein CN, Blanchard JF, Rawsthorne P, et al. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999;149:916-24.
9. Metge C, Chateau D, Prior H, et al. Composite measures/indices of health and health system performance. Winnipeg, MB: Manitoba Centre for Health Policy, 2009.
10. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
11. Nicholls RJ, Clark DN, Kelso L, et al. Nationwide linkage analysis in Scotland implicates age as the critical overall determinant of mortality in ulcerative colitis. Aliment Pharmacol Ther 2010;31:1310-21.
12. Tøttrup A, Erichsen R, Sværke C, et al. Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study. BMJ Open 2012;2:e000823.
13. Kaplan GG, McCarthy EP, Ayanian JZ, et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008;134:680-7.
14. Targownik LE, Singh H, Nugent Z, et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 2012;107:1228-35.
15. Desai A, Zator ZA, De Silva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:309-15.
16. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:30-5.
17. Kopylov U, Ben-Horin S, Zmora O, et al. Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. Inflamm Bowel Dis 2012;18:2404-13.
18. Billioud V, Ford AC, Tedesco ED, et al. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohns Colitis 2013;7:853-67.
19. Nguyen GC, Nugent Z, Shaw S, et al. Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology 2011;141:90-7.
20. Bernstein CN, Loftus EV Jr, Ng SC, et al. Hospitalizations and surgery in Crohn's disease. Gut 2012;61:622-9.
21. Bernstein CN, Ng SC, Lakatos PL, et al. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis 2013;19:2000-10.
22. Höie O, Schouten LJ, Wolters FL, et al. Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis. Gut 2007;56:497-503.
23. Farrokhyar F, Swarbrick ET, Grace RH, et al. Low mortality in ulcerative colitis and Crohn's disease in three regional centers in England. Am J Gastroenterol 2001;96:501-7.
24. Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol 2013;11:43-8.
25. Masala G, Bagnoli S, Ceroti M, et al. Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn's disease patients: the Florence IBD study1978-2001. Gut 2004;53:1309-13.
26. Cosnes J. Smoking, physical activity, nutrition and lifestyle: environmental factors and their impact on IBD. Dig Dis 2010;28:411-17.
27. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in IBD: a population-based study. Gastroenterology 2005;129:827-36.
28. Herrlinger KR, Noftz MK, Dalhoff K, et al. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol 2002;97:377-81.
29. Kuzela L, Vavreka A, Prikazska M, et al. Pulmonary complications in patients with inflammatory bowel disease. Hepatogastroenterology 1999;46:1714-9.
30. Dierkes-Globisch A, Mohr H-H Pulmonary abnormalities in respiratory asymptomatic patients with inflammatory bowel disease. Euro J Int Med 2002;13:385-8.
31. Birring SS, Morgan AJ, Prudon B, et al. Respiratory symptoms in patients with treated hypothyroidism and inflammatory bowel disease. Thorax 2003;58:533-6.
32. Godet PG, Cowie R, Woodman RC, et al. Pulmonary function abnormalities in patients with ulcerative colitis. Am J Gastroenterol 1997;92:7.
33. Songur N, Songur Y, Tuzun M, et al. Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J Clin Gastroenterol 2003;37:292-8.
34. Mahadeva R, Walsh G, Flower CDR, et al. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J 2000;15:41-8.
35. Fireman Z, Osipov A, Kivity S, et al. The use of induced sputum in the assessment of pulmonary involvement in Crohn's disease. Am J Gastroenterol 2000;95:730-4.
36. Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2003;9:104-15.
37. Bernstein CN, Kliewer E, Wajda A, et al. The incidence of cancer among patients with IBD: a population-based study. Cancer 2001;91:854-62.
38. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.
39. Herrinton LJ, Liu L, Levin TR, et al. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998-2010. Gastroenterology 2012;143:382-9.
40. Jess T, Simonsen J, Jørgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012;143:375-81.
41. Soderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009;136:1561-7.